En vivo
FierceBiotechWith ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity raceFierceBiotechThe new standard for trusted AI in biopharmaEndpoints NewsPost-Hoc Live: How much is everyone in biopharma getting paid?BioWorldAppointments and advancements for June 9, 2026BioWorldFinancings for June 9, 2026BioWorldIn the clinic for June 9, 2026BioWorldOther news to note for June 9, 2026BioWorldRegulatory actions for June 9, 2026Endpoints NewsWuXi AppTec added to Pentagon list of companies linked to Chinese militaryMerck & Co.Merck and Gilead discontinue Phase III KEYNOTE-D46/EVOKE-03 study - The Pharma LetterFierceBiotechBial bails after Parkinson’s fail, axing asset over phase 2 missEli LillyAlzeCure Pharma Soars on Major Eli Lilly Alzheimer Deal - TradingPedia
eLife 21 ene 2026

Shifting the PPARγ conformational ensemble toward a transcriptionally repressive state improves covalent inhibitor efficacy

Shifting the PPARγ conformational ensemble toward a transcriptionally repressive state improves covalent inhibitor efficacy

Original
Contenido no disponible. Consulta la fuente original.